|
|
TRAF1 |
TNF receptor associated factor 1 |
- Regulation of TNFR1 signaling
- TNFR1-induced NFkappaB signaling pathway
|
|
|
|
|
TRAF3 |
TNF receptor associated factor 3 |
- TRAF3 deficiency - HSE
- TNFR2 non-canonical NF-kB pathway
- TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
- Ovarian tumor domain proteases
- TICAM1-dependent activation of IRF3/IRF7
- TRAF3-dependent IRF activation pathway
- Negative regulators of DDX58/IFIH1 signaling
- Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
|
|
|
|
|
TRAF6 |
TNF receptor associated factor 6 |
- PIP3 activates AKT signaling
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- Regulated proteolysis of p75NTR
- Downstream TCR signaling
- NRIF signals cell death from the nucleus
- NRIF signals cell death from the nucleus
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Interleukin-1 signaling
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK2 mediated activation of TAK1 complex
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- Alpha-protein kinase 1 signaling pathway
- TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- MyD88 dependent cascade initiated on endosome
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
- MyD88 cascade initiated on plasma membrane
|
|
|
|
|
TRAT1 |
T cell receptor associated transmembrane adaptor 1 |
- PIP3 activates AKT signaling
- Downstream TCR signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|
|
|
TRIM50 |
tripartite motif containing 50 |
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
|
TRIM7 |
tripartite motif containing 7 |
|
|
|
|
|
TRIP10 |
thyroid hormone receptor interactor 10 |
- Rho GTPase cycle
- Clathrin-mediated endocytosis
|
|
|
|
|
TRIP6 |
thyroid hormone receptor interactor 6 |
|
|
|
|
|
TRMO |
tRNA methyltransferase O |
|
|
|
|
|
TRPC6 |
transient receptor potential cation channel subfamily C member 6 |
- Effects of PIP2 hydrolysis
- Elevation of cytosolic Ca2+ levels
- TRP channels
- Role of second messengers in netrin-1 signaling
|
|
- Nephrotic syndrome and focal segmental glomerulosclerosis
|
|
|
TRPV4 |
transient receptor potential cation channel subfamily V member 4 |
|
- Cannabidiol
- Butamben
- Medical Cannabis
- Nabiximols
|
- Spinal muscular atrophy (SMA), including: SMA type I (SMA1) / Werdning-Hoffman disease; SMA type II (SMA2); SMA type III (SMA3) / Kugeleberg-Welander disease; SMA type IV (SMA4); X-linked SMA 2 (SMAX2); X-linked distal SMA 3 (DSMAX); Distal SMA autosomal recessive type 4 (DSMA4); Congenital distal spinal muscular atrophy (SMAL); SMA proximal adult autosomal dominant (SMAPAD)
- TRPV4-related skeletal dysplasias, including: Autosomal dominant brachyolmia; Spondylometaphyseal dysplasia, Kozlowski type (SMDK); Metatropic dysplasia; Spondyloepiphyseal dysplasia, Maroteaux type ; Parastremmatic dysplasia
- TRPV4-related peripheral neuropathies, including: Congenital distal spinal muscular atrophy (CDSMA); Scapuloperoneal spinal muscle atrophy (SPSMA); Hereditary motor and sensory neuropathy type IIC (HMSN IIC)
- Distal hereditary motor neuropathies (dHMN)
|
|
|
TUB |
TUB bipartite transcription factor |
|
- (1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]
|
|
|
|
TXK |
TXK tyrosine kinase |
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
- Fostamatinib
- Zanubrutinib
|
|
|
|
TYRO3 |
TYRO3 protein tyrosine kinase |
|
|
|
|
|
USP8 |
ubiquitin specific peptidase 8 |
- Downregulation of ERBB2:ERBB3 signaling
- Regulation of FZD by ubiquitination
- Ub-specific processing proteases
- Negative regulation of MET activity
|
|
|
|
|
VCL |
vinculin |
- Platelet degranulation
- Smooth Muscle Contraction
- MAP2K and MAPK activation
- Neutrophil degranulation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
|
|
|
|
|
VDR |
vitamin D receptor |
- Vitamin D (calciferol) metabolism
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
|
- Calcitriol
- Calcifediol
- Ergocalciferol
- Cholecalciferol
- Paricalcitol
- Dihydrotachysterol
- Alfacalcidol
- Calcipotriol
- Lexacalcitol
- Seocalcitol
- Cholesterol
- Inecalcitol
- Becocalcidiol
- CTA018
- Eldecalcitol
- Elocalcitol
- Doxercalciferol
- (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol
- 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
- Vitamin D
- Curcumin
- Curcumin sulfate
|
- Tuberculosis
- Localized autosomal recessive hypotrichosis
|
|
|
VIL1 |
villin 1 |
|
|
|
|
|
WAS |
WASP actin nucleation promoting factor |
- Generation of second messenger molecules
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
|
|
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
- Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM)
- Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia
|
|
|
WASL |
WASP like actin nucleation promoting factor |
- Regulation of actin dynamics for phagocytic cup formation
- Regulation of actin dynamics for phagocytic cup formation
- NOSTRIN mediated eNOS trafficking
- Nephrin family interactions
- EPHB-mediated forward signaling
- EPHB-mediated forward signaling
- DCC mediated attractive signaling
- RHO GTPases Activate WASPs and WAVEs
- RHO GTPases Activate WASPs and WAVEs
- Clathrin-mediated endocytosis
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
|
|
|